Advice
in the absence of a submission from the holder of the marketing authorisation:
lacosamide (Vimpat®) is not recommended for use within NHS Scotland.
Indication under review: As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice135KB (PDF)
Medicine details
- Medicine name:
- lacosamide (Vimpat)
- SMC ID:
- 1324/18
- Indication:
- As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 March 2018